Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 5/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | POLQ | O75417 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17682698 | 0.82 | NOS3 (0.39) | TLR9TLR8TLR7MAPK1POLQ | |
| SCHEMBL4049194 | 0.80 | NOS3 (0.34) | GABRA1GABRB2 | |
| SCHEMBL12120832 | 0.78 | NOS2 (0.42) | GABRA1GABRB2 | |
| SCHEMBL803445 | 0.78 | POLB (0.38) | MAPK1CRHR1LMNAGABRA1GABRB2 | |
| SCHEMBL13085751 | 0.76 | ALDH1A1 (0.34) | CRHR1LMNA | |
| SCHEMBL667378 | 0.74 | NOS2 (0.44) | MAPK1MEN1GAAKMT2A | |
| SCHEMBL12899792 | 0.72 | PTGS1 (0.39) | MAPK1POLQCRHR1GAALMNA | |
| SCHEMBL11030024 | 0.72 | ACHE (0.42) | SORDMAPK1MEN1GAAKMT2A | |
| SCHEMBL31574144 | 0.71 | NOTUM (0.38) | MAPK1CRHR1MEN1GAAKMT2A | |
| SCHEMBL22556943 | 0.71 | GRIN2D (0.39) | MAPK1MEN1GAAKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816522-B2 | Triazolone derivatives | EISAI CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20080015199-A1 | Triazolone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015199-A1 | Triazolone derivatives | F3, F12, F2 | SORD 3374/4885TLR9 4604/4885TLR8 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.